Elicera Therapeutics AB banner
E

Elicera Therapeutics AB
STO:ELIC

Watchlist Manager
Elicera Therapeutics AB
STO:ELIC
Watchlist
Price: 5.74 SEK -11.69% Market Closed
Market Cap: kr278.6m

Wall Street
Price Targets

ELIC Price Targets Summary
Elicera Therapeutics AB

Wall Street analysts forecast ELIC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ELIC is 8.36 SEK with a low forecast of 8.28 SEK and a high forecast of 8.61 SEK.

Lowest
Price Target
8.28 SEK
44% Upside
Average
Price Target
8.36 SEK
46% Upside
Highest
Price Target
8.61 SEK
50% Upside
Elicera Therapeutics AB Competitors:
Price Targets
VNOM
Viper Energy Partners LP
20% Upside
HOTH
Hoth Therapeutics Inc
407% Upside
STG
Strip Tinning Holdings PLC
143% Upside
IBEX
Ibex Ltd
43% Upside

Revenue
Forecast

1 060% / Year
Past Growth
91% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
1 060% / Year
Past Growth
91% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

For the last 4 years the compound annual growth rate for Elicera Therapeutics AB's revenue is 1 060%. The projected CAGR for the next 2 years is 91%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-55%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-55%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ELIC's stock price target?
Price Target
8.36 SEK

According to Wall Street analysts, the average 1-year price target for ELIC is 8.36 SEK with a low forecast of 8.28 SEK and a high forecast of 8.61 SEK.

What is Elicera Therapeutics AB's Revenue forecast?
Projected CAGR
91%

For the last 4 years the compound annual growth rate for Elicera Therapeutics AB's revenue is 1 060%. The projected CAGR for the next 2 years is 91%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett